Left ventricular hypertrophy: renin4angiotensin system role

Left ventricular hypertrophy: renin4angiotensin system role

The review presents modern views on pathogenetic mechanisms of myocardial hypertrophy, with the key role played by renin-angiotensin system (RAS) activation and hemodynamic overload. The authors analyze main structural and functional disturbances typical for and underlying the clinical manifestation...

Full description

Saved in:

Bibliographic Details
Main Authors:	F. T. Ageev, A. G. Ovchinnikov, V. M. Serbul, Yu. N. Belenkov
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2008-04-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	arterial hypertension left ventricular hypertrophy renin-angiotensin system angiotensin receptor blockers ace inhibitors
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1338
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Left ventricular hypertrophy: prognostic value, pathogenesis, possible remodeling: focusing on angiotensin receptor antagonists
by: M. D. Smirnova, et al.
Published: (2007-12-01)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
by: Juan Meng, et al.
Published: (2020-01-01)

EFFECT OF ANGIOTENSIN-II RECEPTOR ANTAGONIST LOSARTAN AND ITS COMBINATION WITH DIURETICS ON MYOCARDIAL MORPHO-FUNCTIONAL CONDITIONS IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY
by: S. N. Tolpygina, et al.
Published: (2016-01-01)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

Comparative effect of ARNI and ACEI/ARB on left ventricular diastolic function in patients with hypertensive heart disease
by: YANG Hao, et al.
Published: (2025-06-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2012-09-01)

Angiotensin II type 1 receptor antagonists and ACE inhibitors in the regulation of hemodynamics and renin-angiotensin-aldosterone system activity: focus on the organ protection
by: M. L. Maksimov, et al.
Published: (2010-04-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study
by: Busayo Onafowoke Oguntola, et al.
Published: (2025-01-01)

Angiotensin Converting Enzyme Inhibitors: Interaction Issues in Patients with Glaucoma and Arterial Hypertension. Review
by: S. I. Makogon, et al.
Published: (2023-12-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

Cinnamic acid alleviates hypertensive left ventricular hypertrophy by antagonizing the vasopressor activity and the pro-cardiac hypertrophic signaling of angiotensin II
by: Yimeng Cui, et al.
Published: (2025-02-01)

The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus
by: O. K. Vikulova, et al.
Published: (2020-08-01)

RENIN-ANGIOTENSIN SYSTEM IN REGULATION OF HEMATOPOIESIS
by: M. L. Kanaeva, et al.
Published: (2018-02-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Modulation of the renin-angiotensin system against COVID-19: A path forward?
by: Serge Camelo, et al.
Published: (2025-05-01)

Renin–angiotensin system inhibition in COVID-19 patients: Friend or foe?
by: Bilgehan Karadağ
Published: (2020-07-01)

Evaluating the risks and benefits of continuing versus withholding renin–angiotensin system inhibitors: a systematic review and meta-analysis with trial sequential analysis
by: Laila Shalabi, et al.
Published: (2025-06-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

Novel Antihypertensive Medications to Target the Renin-Angiotensin System: Mechanisms and Research
by: Zhe Jiang, et al.
Published: (2025-04-01)

Calcium Channel Blocker Versus Renin–Angiotensin System Inhibitor in Risk of Kidney Cancer Among Patients With Hypertension: A Propensity Score‐Matched Cohort Study
by: Minji Jung, et al.
Published: (2024-11-01)

Efficacy of angiotensin receptor blockers for erectile dysfunction in hypertensive men: A systematic review
by: Swati Sucharita Dash, et al.
Published: (2024-01-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

THE RENIN-ANGIOTENSIN SYSTEM AND ITS INVOLVEMENT IN PAIN CONTROL. A NEW INSIGHT INTO AN OLD SYSTEM
by: Daniela Pechlivanova, et al.
Published: (2025-04-01)

EFFECTS OF VITAMIN D ON THE RENIN-ANGIOTENSIN SYSTEM
by: L. Pashova-Stoyanova, et al.
Published: (2019-09-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

THE GENDER FEATURES OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: V. I. Podzolkov, et al.
Published: (2016-01-01)

IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-07-01)

The renin-angiotensin system in healthy human platelets: expressed but inactive
by: François Panosetti, et al.
Published: (2025-12-01)

Comparison of angiotensin converting enzyme 1 levels to the grading of knee osteoarthritis
by: Fidelia Elvira Da Costa Rao, et al.
Published: (2024-06-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

Myocardial functional status in patients with arterial hypertension and hyperaldosteronism: orthogonal electrocardiography assessment
by: Kh. F. Samedova, et al.
Published: (2006-04-01)

The role of the classical renin–angiotensin system and angiotensin-converting enzyme 2/Ang(1–7)/Mas axis in pulmonary fibrosis
by: Changhui Lang, et al.
Published: (2025-07-01)

Renin-angiotensin and kallikrein-kinin systems in diabetic renal damage
by: Igić Rajko
Published: (2019-01-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

Imidazoline receptor agonists and left ventricular hypertrophy
by: L. L. Kirichenko, et al.
Published: (2005-04-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Is Associated With a Reduced Risk of Poststroke Epilepsy in Patients With Ischemic Stroke
by: Kuo‐Cheng Chang, et al.
Published: (2024-09-01)